A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Jade101 Administered Subcutaneously in Participants with IgAN October 24, 2026
A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of JADE101 in Participants with Immunoglobulin A Nephropathy October 24, 2026
Model-Based Assessment of Clinical Responses to APRIL Blockade Informing Development of the anti-APRIL mAb JADE101 in IgAN October 22, 2026
Characterization and Development of JADE301, a Half-Life Extended Anti-IFN-β Monoclonal Antibody for Treatment of Dermatomyositis October 16, 2026
A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of JADE101 in Participants with IgAN June 5, 2026
Interim Results of a Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 in Healthy Volunteers June 5, 2026
Translational Framework to Predict Clinical Responses to APRIL Blockade for Development of JADE101 November 8, 2025